Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

How may GIP enhance the therapeutic efficacy of GLP-1?

Samms RJ, Coghlan MP, Sloop KW. Trends in Endocrinology & Metabolism 2020

Document identifier
CEI-BR-097
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Samms RJ, Coghlan MP, Sloop KW
Title
How may GIP enhance the therapeutic efficacy of GLP-1?
Source
Trends in Endocrinology & Metabolism
Year
2020
Volume, issue, pages
31(6):410–421
Digital object identifier
10.1016/j.tem.2020.02.006
PubMed identifier
32396843
Record type
Journal article
Institute identifier
CEI-BR-097

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

§1.3Subject tags

gip mechanism review

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.